A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Conditions:Lung Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Bladder Cancer
Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:October 1, 2018
End Date:October 2020
Contact:Yoshiya Yamada, MD

Use our guide to learn which trials are right for you!

A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint Blockade

Drugs called checkpoint inhibitors help the immune system fight cancer. When the
effectiveness of these drugs wears off, it may be possible to renew their effectiveness by
combining it with a special type of radiation therapy called stereotactic body radiation
therapy (SBRT). SBRT is a commonly used type of radiation therapy that gives high dose
radiation with high precision to tumors in 1-5 treatments. Radiation therapy, such as SBRT
can also treat sites of metastases. The use of checkpoint inhibitors in combination with SBRT
has been suggested to improve the immune response against cancer but has not been tested in a
formal clinical trial. Up to three lesions can be treated with SBRT. This study only allows
checkpoint inhibitors that are already approved by the Federal Drug Agency (FDA) for the
treatment of your disease. All radiation therapy will be done on machines which are FDA

Inclusion Criteria:

- Subjects must have signed and dated an IRB approved written informed consent form in
accordance with regulatory and institutional guidelines.

- Subjects must be willing and able to comply with scheduled visits, treatment schedule,
laboratory testing, and other study obligations.

- Males and females ≥ 18 years of age.

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

- Histologically confirmed metastatic cancer of any histology for which there is an FDA
indication for an immune checkpoint inhibitor including melanoma, lung, bladder, renal
and head/neck cancers.

- Patient has been receiving treatment with an immune checkpoint inhibitor including but
not limited to ipilimumab, nivolumab, avelumab, durvalumab, pembrolizumab,
atezolizumab, and tremelimumab for at least 2 months. A combination of these therapies
is also permitted. No max prior lines of therapy.

- Patient has evidence of limited progression (up to 5 lesions either new or increase in
at least 25% in the cross-sectional diameter of a known lesion) on most recent
systemic imaging as determined by the treating physician. Patients with greater than 5
lesions can be included after discussion with the study investigators.

- Patient must be eligible to continue to receive an immune checkpoint inhibitor after

- Subjects must have at least two lesions:

- One lesion must be safely amenable to irradiation in the opinion of the treating
radiation oncologist. This can be a lesion that was previously irradiated if it
is deemed appropriate by the treating physician and principal investigator.
Standard MSKCC re-irradiation dose constraints must be met.

- At least one, not-to-be-irradiated lesion measurable by CT or MRI per RECIST 1.1

- Prior palliative or curative radiotherapy must be completed at least 14 days prior to

- Immunosuppressive doses of systemic medication, such as steroids or absorbed topical
steroids (doses >10mg/day prednisone or equivalent) must be discontinued at least 14
days prior to radiotherapy administration.

- Women of childbearing potential must have a negative serum within 7 days prior to
treatment, or urine pregnancy test (within 24 hours) (minimum sensitivity 25 IU/L or
equivalent units of HCG). Women of childbearing potential must agree to follow
instructions for method(s) of contraception from time of enrollment for the duration
of treatment.

- Men who are sexually active with WOCBP must use any contraceptive method with a
failure rate of less than 1% per year.


- Women who are not of childbearing potential i.e., who are postmenopausal or surgically
sterile as well as azoospermia men do not require contraception.

- Azoospermic males, and women of childbearing potential who are continuously not
heterosexually active, are exempt from contraceptive requirements. However, they still
must have a pregnancy test.

- Exclusion Criteria:

- Active brain metastases (untreated brain metastases or growth on imaging as
defined below) or leptomeningeal disease are not allowed. Subjects with brain
metastases are eligible if these have been treated and there is no MRI (or CT if
MRI contraindicated) evidence of progression for at least 8 weeks after treatment
for these metastases is complete and within 28 days prior to first study

- Any medical disorder that, in the opinion of the investigator, might increase the
risk associated with study participation or interferes with the interpretation of
study results.

- Prior active malignancy within the previous 3 years except for locally curable
cancers such as basal or squamous skin cancer, superficial bladder, low risk
prostate cancer, breast, or cervix cancer. If other prior malignancy was active
within prior 3 years, enrollment requires approval of a principal investigator.

- Patients should be excluded if they have an active, known or suspected autoimmune
disease. Subjects are permitted to enroll if they have vitiligo, type I diabetes
mellitus, residual hypothyroidism due to autoimmune condition only requiring
hormone replacement, psoriasis not requiring systemic treatment, or conditions
not expected to recur in the absence of an external trigger

- Subjects requiring systemic treatment with either corticosteroids (> 10 mg daily
prednisone equivalents for greater than 5 days) or other immunosuppressive
medications within 14 days of study drug administration should be excluded.
Inhaled or topical steroids and adrenal replacement doses >10mg daily prednisone
equivalents are permitted in the absence of active autoimmune disease.

- Treatment with any other chemotherapy, radiation therapy, biologics for cancer,
or investigational therapy concurrently or within 14 days of enrollment

- History of allergy to checkpoint inhibitors

- History of severe hypersensitivity reaction to any monoclonal antibody.

- Women must not be breastfeeding.
We found this trial at
Basking Ridge, New Jersey 07920
Phone: 212-639-2950
Basking Ridge, NJ
Click here to add this to my saved trials
Commack, New York 11725
Phone: 212-639-2950
Commack, NY
Click here to add this to my saved trials
Harrison, New York
Phone: 212-639-2950
Harrison, NY
Click here to add this to my saved trials
480 Red Hill Road
Middletown, New Jersey 07748
Phone: 212-639-2950
Middletown, NJ
Click here to add this to my saved trials
225 Summit Avenue
Montvale, New Jersey 07645
Phone: 212-639-2950
Montvale, NJ
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Yoshiya Yamada, MD
Phone: 212-639-2950
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
New York, NY
Click here to add this to my saved trials
Rockville Centre, New York 11570
Phone: 212-639-2950
Rockville Centre, NY
Click here to add this to my saved trials
Uniondale, New York 11553
Phone: 212-639-2950
Uniondale, NY
Click here to add this to my saved trials